ATE425764T1 - Verwendung von igf-1 allein oder kombiniert mit dem wachstumsfaktor zur stimulierung des wachstums - Google Patents

Verwendung von igf-1 allein oder kombiniert mit dem wachstumsfaktor zur stimulierung des wachstums

Info

Publication number
ATE425764T1
ATE425764T1 AT99123825T AT99123825T ATE425764T1 AT E425764 T1 ATE425764 T1 AT E425764T1 AT 99123825 T AT99123825 T AT 99123825T AT 99123825 T AT99123825 T AT 99123825T AT E425764 T1 ATE425764 T1 AT E425764T1
Authority
AT
Austria
Prior art keywords
hormone
binding protein
growth
bound
lifa
Prior art date
Application number
AT99123825T
Other languages
English (en)
Inventor
Lena Mariana Susann Carlsson
Ross Graham Clark
Wai Lee Tan Wong
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE425764T1 publication Critical patent/ATE425764T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/61—Growth hormones [GH] (Somatotropin)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT99123825T 1990-11-19 1991-11-19 Verwendung von igf-1 allein oder kombiniert mit dem wachstumsfaktor zur stimulierung des wachstums ATE425764T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/615,538 US5210017A (en) 1990-11-19 1990-11-19 Ligand-mediated immunofunctional hormone binding protein assay method

Publications (1)

Publication Number Publication Date
ATE425764T1 true ATE425764T1 (de) 2009-04-15

Family

ID=24465822

Family Applications (3)

Application Number Title Priority Date Filing Date
AT99123825T ATE425764T1 (de) 1990-11-19 1991-11-19 Verwendung von igf-1 allein oder kombiniert mit dem wachstumsfaktor zur stimulierung des wachstums
AT92901281T ATE138739T1 (de) 1990-11-19 1991-11-19 Durch den liganden vermitteltes immunofunktionelles verfahren zur bestimmung hormonbindender proteine
AT95110334T ATE213165T1 (de) 1990-11-19 1991-11-19 Pharmazeutische zusammensetzung enthaltend wachstumshormon und wachstumshormon- bindungsprotein

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT92901281T ATE138739T1 (de) 1990-11-19 1991-11-19 Durch den liganden vermitteltes immunofunktionelles verfahren zur bestimmung hormonbindender proteine
AT95110334T ATE213165T1 (de) 1990-11-19 1991-11-19 Pharmazeutische zusammensetzung enthaltend wachstumshormon und wachstumshormon- bindungsprotein

Country Status (11)

Country Link
US (1) US5210017A (de)
EP (3) EP0681842B1 (de)
JP (2) JP2977280B2 (de)
AT (3) ATE425764T1 (de)
AU (1) AU657109B2 (de)
CA (1) CA2093927C (de)
DE (3) DE69132931T2 (de)
DK (3) DK0558647T3 (de)
ES (3) ES2324322T3 (de)
GR (1) GR3020505T3 (de)
WO (1) WO1992008985A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866350A (en) * 1985-03-19 1999-02-02 Helen Hwai-An Lee Method for the immunological determination of a biological material in a sample
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5593844A (en) * 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US6326154B1 (en) * 1990-11-19 2001-12-04 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5464757A (en) * 1991-01-15 1995-11-07 The Salk Institute For Biological Studies DNA encoding CRF binding protein
ES2286868T3 (es) * 1992-07-31 2007-12-01 Genentech, Inc. Composicion acuosa a base de hormana del crecimiento humana.
US6087188A (en) * 1992-11-13 2000-07-11 Alk A/S Two-site immunoassay for an antibody with chemiluminescent label and biotin bound ligand
JPH08500740A (ja) * 1993-06-25 1996-01-30 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー リポタンパク質関連ホスホリパーゼａ▲下２▼、その阻害剤および診断および治療におけるその使用
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US7885697B2 (en) 2004-07-13 2011-02-08 Dexcom, Inc. Transcutaneous analyte sensor
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
DE60016560T2 (de) * 1999-01-06 2005-12-15 Genentech, Inc., South San Francisco Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
DE60133271T2 (de) * 2000-05-16 2009-04-23 Genentech, Inc., South San Francisco Behandlung von knorpelerkrankungen
US7108993B2 (en) * 2002-07-19 2006-09-19 Bayer Healthcare Llc Use of dual conjugated labels in the elimination of serum interference in immunochromatographic assays
SE0300959D0 (sv) * 2002-12-19 2003-04-02 Pharmacia Ab Methods for predicting therapeutic response to agents acting on the growth hormone receptor
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
ATE536186T1 (de) 2003-09-12 2011-12-15 Tercica Inc Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
WO2006127694A2 (en) 2004-07-13 2006-11-30 Dexcom, Inc. Analyte sensor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE263537C (de) *
NL7501215A (nl) * 1975-02-01 1976-08-03 Akzo Nv Methode voor het aantonen en bepalen van een antigeen of antilichaam.
US4486530A (en) * 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4476228A (en) * 1982-11-08 1984-10-09 Abbott Laboratories Determination of unsaturated thyroxine binding protein sites using fluorescence polarization techniques
US4622293A (en) * 1983-07-05 1986-11-11 Miles Laboratories, Inc. Iodothyronine immunoassays employing HMS as TBP blocking agent
US4594327A (en) * 1983-11-02 1986-06-10 Syntex (U.S.A.) Inc. Assay method for whole blood samples
ATE97498T1 (de) * 1984-01-30 1993-12-15 Imp Cancer Res Tech Verbesserungen an wachstumsfaktoren.
US4737456A (en) * 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5057417A (en) * 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
DD263537A1 (de) * 1987-09-01 1989-01-04 Akad Wissenschaften Ddr Verfahren zur herstellung von monoklonalen antikoerpern gegen humanes wachstumshormon
US4956302A (en) * 1987-09-11 1990-09-11 Abbott Laboratories Lateral flow chromatographic binding assay device
WO1989007271A1 (en) * 1988-01-28 1989-08-10 E.I. Du Pont De Nemours And Company Immunoassays using monoclonal antibodies directed against natural binding proteins
DK131988A (da) * 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
ATE132164T1 (de) * 1988-04-12 1996-01-15 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
EP0424416B1 (de) * 1988-07-15 1995-07-19 Central Sydney Area Health Service Säureempfindliche subeinheit eines insulinähnlichen wachstumfaktors-bindeprotein-komplexes
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
US5330971A (en) * 1989-06-09 1994-07-19 Gropep Pty. Ltd. Growth hormone fusion proteins, methods of production, and methods of treatment
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy

Also Published As

Publication number Publication date
WO1992008985A3 (en) 1992-10-29
EP0681842A2 (de) 1995-11-15
WO1992008985A2 (en) 1992-05-29
JP2977280B2 (ja) 1999-11-15
EP0681842A3 (de) 1998-06-10
DE69119911T2 (de) 1996-11-21
DE69132931T2 (de) 2002-11-28
HK1007351A1 (en) 1999-04-09
ES2171478T3 (es) 2002-09-16
ES2090598T3 (es) 1996-10-16
DK0681842T3 (da) 2002-06-03
EP0995445B1 (de) 2009-03-18
EP0558647B1 (de) 1996-05-29
ATE138739T1 (de) 1996-06-15
DE69132931D1 (de) 2002-03-21
EP0995445A2 (de) 2000-04-26
CA2093927C (en) 2000-07-18
EP0681842B1 (de) 2002-02-13
DK0558647T3 (da) 1996-08-19
JPH06502724A (ja) 1994-03-24
EP0558647A1 (de) 1993-09-08
GR3020505T3 (en) 1996-10-31
DE69133614D1 (de) 2009-04-30
ATE213165T1 (de) 2002-02-15
DE69119911D1 (de) 1996-07-04
EP0995445A3 (de) 2004-01-07
JP3159966B2 (ja) 2001-04-23
CA2093927A1 (en) 1992-05-20
DK0995445T3 (da) 2009-07-06
AU9106791A (en) 1992-06-11
AU657109B2 (en) 1995-03-02
US5210017A (en) 1993-05-11
ES2324322T3 (es) 2009-08-04
JPH11346765A (ja) 1999-12-21

Similar Documents

Publication Publication Date Title
ATE425764T1 (de) Verwendung von igf-1 allein oder kombiniert mit dem wachstumsfaktor zur stimulierung des wachstums
VAN WYK et al. Evidence from radioligand assays that somatomedin-C and insulin-like growth factor-I are similar to each other and different from other somatomedins
DE60042617D1 (de) Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
IL101728A0 (en) Human notch and delta,binding domains in toporhythmic proteins,and methods based thereon
NO964650L (no) LAG-3 proteinopploselige polypeptidfraksjoner, fremgangsmate for fremstilling, terapeutisk preparat og anti-idiotype antistoff
ATE140963T1 (de) Verfahren zur herstellung von sekretierten rezeptoranalogen
EP0150735A3 (en) Method and composition for preparation of factor viiic
IL96043A0 (en) Polypeptides complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known
Merchenthaler et al. Immunocytochemical localization of growth hormone releasing factor (GHRF)-containing structures in the rat brain using anti-rat GHRF serum
ATE366420T1 (de) Kit und verfahren zur bestimmung von protein esm- 1
EP0514173A3 (en) Methods and compositions for enzyme complementation assays using the omega region of beta-galactosidase
CA2291983A1 (en) Ligand-mediated immunofunctional hormone binding protein assay method
Tashjian Jr et al. Human calcitonin: application of affinity chromatography
Smith et al. A parotid salivary protein present during late pregnancy and postpartum
Mallette Immunoreactivity of human parathyroid hormone (28-48): attempt to develop an assay for intact human parathyroid hormone
Carlsson et al. Ligand-mediated immunofunctional hormone binding protein assay method

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0995445

Country of ref document: EP

EELA Cancelled due to lapse of time